Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce that is has filed a new patent regarding the use of the novel technology in Sol for the prevention and treatment of solar keratosis and related cancers of the skin.
The patent, if granted, will further extend the life of the patent family protecting Sol to 2041.
The Company looks forward to updating on progress relating to the development and commercialisation of Sol in due course.
Commenting on the filing of the patent, Chairman, Tim McCarthy said:
“This new patent filing demonstrates the robust foundations of our Sol programme and strengthens the commercial protection for the product. We are looking forward to the next steps as we bring Sol forward to market-facing partners.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
The directors of the Company take responsibility for this announcement.
For further enquiries:
Tim McCarthy, Chairman
+44 (0) 7831 675747
Simon Ward, Chief Executive Officer
+44 (0) 7747 625506
Suzanne Brocks, Head of Communications
+44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis
+44 (0) 20 7213 0880
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney
+44 (0) 20 3815 8880
Notes to Editors:
Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics (“ICT”) at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
Download full PDF